Navigation Links
Lilly Reports Third-Quarter 2013 Results
Date:10/23/2013

>Income related to termination of the exenatide collaboration with Amylin

 

-

 

.04

 

(.43)Earnings per share (non-GAAP)  $1.11$0.7941%Year-to-Date Results
For the first nine months of 2013, worldwide total revenue was $17.304 billion, an increase of 4 percent compared with the same period in 2012. Reported net income and earnings per share were $3.957 billion and $3.64, respectively. Net income and earnings per share, on a non-GAAP basis, were $3.706 billion and $3.41, respectively.

Non-GAAP measures exclude items totaling $0.23 and $0.38 per share of income for the first nine months of 2013 and 2012, respectively. For further detail, see the reconciliation below as well as the Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information table later in this press release. Year-to-date20132012

% ChangeEarnings per share (reported)$3.64$2.9225%Asset impairment, restructuring and other special charges

 

.06 

.05Income related to termination of the exenatide collaboration with Amylin

 

(.29) 

(.43)Earnings per share (non-GAAP)  $3.41$2.5434% Revenue Highlights 

(Dollars in millions)

 

Third Quarter

% Change
Over/(Under)

 

Year-to-Date

% Change
Over/(Under)20132012

2012

2013

2012

2012Cymbalta

$1,375.8$1,235.811%$4,201.2$3,573.718%Alimta

690.5643.67%1,976.81,909.94%Humalog

616.0575.87%1,877.41,779.56%Cialis®

526.7482.19%1,571.11,413.411%Humulin®

307.0285.48%946.3896.16%Forteo

306.7288.76%885.2836.46%Zyprexa

278.7374.5(26)%846.71,316.6(36)%Evista

255.3247.03%774.6769.21%Strattera®

173.2145.619%508.1457.511%Effient®

124.9109
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. FDA Grants Lillys Ramucirumab Priority Review as a Potential Single-Agent Treatment for Advanced Gastric Cancer
2. Lilly Declares Fourth-Quarter 2013 Dividend
3. Lilly Reintegration Scholarship Applications Available for 2014-2015 Academic Year
4. Lilly to host investment community meeting at its Indianapolis headquarters on Thursday, October 3, 2013
5. Data Presented at 49th EASD Annual Meeting Show Treatment with Lillys Investigational Dulaglutide Resulted in Improved Patient-Reported Health Outcomes
6. Lilly Announces Second Positive Ramucirumab Phase III Gastric Cancer Study Meets Primary Endpoint; Phase III Lilly/TRIO Breast Cancer Study Misses Primary Endpoint
7. Exosome Diagnostics Enters Collaboration Agreement with Lilly for Exosome Blood-Based Biomarker Discovery
8. Lilly to Present Data Across its Diabetes Portfolio at the 49th European Association for the Study of Diabetes Annual Meeting
9. Humana and Lilly Form Research Collaboration to Improve Health Care Outcomes
10. Dr. Marschall S. Runge Elected to Lilly Board of Directors
11. Lilly Reports Second-Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 Regen BioPharma, Inc. (OTCBB: RGBP) ... novel means of delivering its patented (US Patent ... tumors utilizing a clinically approved formulation as delivery ... with gene silencing therapeutics in which the gene ... whole body.  By utilizing a local delivery system, ...
(Date:8/31/2015)... and MOUNTAIN VIEW, Calif. , Aug. ... ; EURONEXT: SAN) and the life sciences team at ... care and outcomes for people with type 1 and ... treatments and devices with Google,s expertise in analytics, miniaturized ... explore how to improve diabetes care by developing new ...
(Date:8/31/2015)...  Qualcomm Incorporated (NASDAQ: QCOM ) today ... is collaborating with Davita Healthcare Partners and ... by Qualcomm Life,s 2net™ Device Connectivity Platform and ... informed interventions and better management of at-risk populations. ... Connect 2015 ecosystem conference taking place ...
Breaking Medicine Technology:Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 2Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 3Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 4Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 5Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes 6Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 2Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 3Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 4Qualcomm Life Announces New Connected Health Collaborations at Connect 2015 5
... 7, 2011  Tethys Bioscience has entered into an agreement ... employers measurably flatten the trajectory of their healthcare trends ... their employee populations. The agreement allows ACAP Health to ... as a component of its disease intervention programs. The ...
... 2011 Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ... and develops new uses for previously approved drugs and ... of the granting of a European patent with broad ... diketopiperazine which is the active ingredient of Ampion™.  The ...
Cached Medicine Technology:Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 2Tethys Bioscience and ACAP Health Consulting Partner to Help Employers Prevent Diabetes 3Ampio Pharmaceuticals Awarded European Patent that Strengthens Intellectual Property Protection for its key drug Ampion™ 2
(Date:8/31/2015)... ... August 31, 2015 , ... Jvion, the ... latest predictive use case focused on helping hospital perform under the Center for ... hospital payments are adjusted based on performance across four domains related to care ...
(Date:8/31/2015)... ... 31, 2015 , ... Dental clinicians from Newcastle University, United ... to learn more about its integrated approach to diabetes care. , Philip Preshaw, ... Cellular Medicine at Newcastle University, and Susan Bissett, National Institute for Health Research ...
(Date:8/31/2015)... ... August 31, 2015 , ... India Network ... “ InstantQuote ” tool, which summarizes all available plans, plan maximums, pre-existing condition ... is designed to help India Network members make an informed decision regarding the ...
(Date:8/31/2015)... (PRWEB) , ... August 31, 2015 , ... ... is a one-day event geared to patients and family members, medical professionals, ... local and regional mesothelioma experts. The conference is a collaborative effort between the ...
(Date:8/31/2015)... ... August 31, 2015 , ... Coast Dental Vista ... 5, 2015, from 11 a.m. to 3 p.m. near Albertsons in the Foothill Center, ... to meet Dr. Ofelia Rivera and Dr. Jay Lopp. Call (760) 208-2518 for more ...
Breaking Medicine News(10 mins):Health News:Jvion Releases Value-Based Purchasing Predictive Use Case 2Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:India Network proudly launches the new InstantQuote tool to help choose right visitor health insurance with pre-existing conditions to US bound visitors 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 2Health News:New York Experts on Mesothelioma Come Together at Memorial Sloan Kettering Cancer Center 3Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 2Health News:Discover How to Replace Missing Teeth, Reduce Cavities, and Restore Oral Health During Coast Dental’s Open House in Vista, CA on Sept. 5, 2015 3
... in the United States will contract a sexually transmitted ... and Prevention. Experts believe a major contributing factor is ... and routinely. Now a new study provides some insight ... among teenagers. , Researchers from the Bradley ...
... Professional Postgraduate Services® (PPS®), renowned for its award-winning healthcare ... RSV and pediatric influenza, Preventing and Managing RSV Disease ... on PediatricRespiratory.org. , ... ...
... company, is thrilled to be included in Inc.,s 27th ... in the country. As the fastest growing company in ... to other healthcare staffing firms making the list it ... traveling healthcare staffing companies. It is the only company ...
... Universal,Health Services, Inc. (NYSE: UHS ) ... to sell Central Montgomery Medical Center, a 125 ... Abington Memorial,Hospital. The sale is subject to customary ... later this fall., UHS also announced that ...
... PITTSBURGH, Sept. 8 Mylan Inc. (NYSE: ... to market and other,conditions, $400 million principal amount ... offering to qualified institutional buyers pursuant,to Rule 144A ... (the "Securities,Act"). Mylan also expects to grant the ...
... spasms are a severe and potentially devastating epilepsy condition ... study appearing in Epilepsia, researchers have found ... diet more traditionally used for intractable childhood epilepsy, is ... The study is the first description of the ketogenic ...
Cached Medicine News:Health News:Teens' failure to use condoms linked to partner disapproval, fear of less sexual pleasure 2Health News:PediatricRespiratory.org Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza 2Health News:PediatricRespiratory.org Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza 3Health News:PediatricRespiratory.org Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza 4Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 2Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 3Health News:Medical Solutions Ranks No. 472 in the 2008 Inc. 500 with Three-Year Sales Growth of 667.8% 4Health News:Universal Health Services, Inc. Announces Sale of Acute Care Hospital and Addition of Two Behavioral Health Hospitals 2Health News:Mylan to Offer $400 Million in Cash Convertible Notes 2Health News:Mylan to Offer $400 Million in Cash Convertible Notes 3Health News:Diet may eliminate spasms for infants with epilepsy 2
Open blade design with aspiration capabilities for removing fluids from the operative site. 19 gauge wire....
Designed to provide open approaches of the keratome to the cornea for either the left or right eye. Lightweight wire design adds to the comfort of the instrument when in place....
Solid 14 mm free-swinging blades, suture posts, and stabilizing disk. Dull finish....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: